Servier Pharmaceuticals is a commercial-stage pharmaceutical company governed by a non-profit foundation, with current treatments for patients with acute lymphoblastic leukemia (ALL). As a privately held company, Servier have the freedom to maintain a steady focus on the most urgent needs of patients. Their independence allows them to be more forward thinking and make sustainable choices for the long-term. With this unique operating model, the company can be deliberate about putting patients ahead of profits, re-investing 25 percent of revenue into Research and Development each year. Building out their U.S. presence in 2018, with their headquarters in Boston, MA they are driven by discovery in oncology and potentially other areas of unmet medical need. They leverage Servier Group’s global portfolio and seek acquisitions, licensing deals and partnerships. Poised to be an innovative leader serving U.S. patients and caregivers.